Evaluation of the impact of eicosapentaenoic acid on postprandial hyperglycemia, hyperliopemia and endothelial dysfunction in mild diabetic and impaired glucose tolerance patients with coronary artery disease.

Evaluation of the impact of eicosapentaenoic acid on postprandial hyperglycemia, hyperliopemia and endothelial dysfunction in mild diabetic and impaired glucose tolerance patients with coronary artery disease. - Evaluation of the impact of eicosapentaenoic acid on postprandial hyperglycemia, hyperliopemia and endothelial dysfunction in mild diabetic and impaired glucose tolerance patients with coronary artery disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011265

Enrollment

Registered

2013-08-13

Start date

2013-08-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

untreated mild diabetic patients (HbA1c&lt

Interventions

eicosapentanoeic acid life style improvement

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Impaired glucose tolearance patients diagnosed by 75g carbohydrate tolerance test or untreated mild diabetic patients (HbA1c<7.0%)

Exclusion criteria

Exclusion criteria: chronic renal failure (Cr>2.0mg/dL) steroid user chronic inflammatory disease (infection, collagen disease, malignant disease)

Design outcomes

Primary

Measure	Time frame
Flow-mediated dilatation as an endothleial function after 6 months treatment.	—

Secondary

Measure	Time frame
postprandial hyperglycemia and hyperlipemia after cookie meal test after 6months treatment.	—

Countries

Japan

Contacts

Public ContactTakahiro Sawada

Hyogo Brain and Heart Center Division of Cardiovascular medicine

taktak319@yahoo.co.jp079-293-3131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026